Agenus Inc.;Memorial Sloan-Kettering Cancer Center;Ludwig Institute for Cancer Research Ltd.
发明人:
Marc VAN DIJK,Ekaterina V. BREOUS-NYSTROM,Volker SEIBERT,Gerd RITTER,David SCHAER,Daniel HIRSCHHORN-CYMERMAN,Taha MERGHOUB,Hao TANG,David A. SAVITSKY,Jeremy WAIGHT,Nicholas S. WILSON
申请号：
US16384116
公开号：
US20190352410A1
申请日:
2019.04.15
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
